2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2251

Preferences for Physical Activity: A Discrete Choice Experiment in People with Chronic Knee Pain
Abstract Number: 6

Pregnancy Outcomes in a Cohort of Women with Antiphospholipid Syndrome. 25- Years Long-Term Observation
Abstract Number: 1311

Pregnancy Outcome in Chinese Women with Rheumatic Disease Treated By Leflunomide (LEF)
Abstract Number: 1295

Pregnancy Outcome in Patients with SLE Compared to Patients with Other Inflammatory Rheumatic Diseases: Real World Data from a Prospective Pregnancy Register
Abstract Number: 1312

Pregnancy Outcomes in Male Patients Using Anti-Tumor Necrosis Factor Alpha Patients with Inflammatory Arthritis; Hur-BIO Real Life Experiences
Abstract Number: 2804

Pregnancy Outcomes in Patients with Ankylosing Spondylitis: A Nationwide Population Study
Abstract Number: 1314

Pregnancy Outcomes in Patients with Psoriasis: A Nationwide Population-Based Study
Abstract Number: 2823

Preliminary Comparison of Patient-Centered Weight Loss Programs Starting before Versus after Knee Replacement
Abstract Number: 1482

Preliminary Population-Based Incidence and Prevalence Estimates of Primary Sjogren’s Syndrome from the Manhattan Lupus Surveillance Program
Abstract Number: 356

Preliminary Real World Data on Switching Patterns between Etanercept, Its Recently Marketed Biosimilar Counterpart and Its Competitor Adalimumab, Using Swedish Prescription Registry
Abstract Number: 2877

Premature Senescence of Naive CD4+ T-Cells in Primary Sjogren’s Syndrome
Abstract Number: 2646

Premature Senescence of Naive CD4+ T-Cells in Systemic Lupus Erythematosus
Abstract Number: 1034

Presence of Anti-Cyclic Citrullinated Peptide Antibodies Is Associated with Better Treatment Response to Abatacept but Not to TNF Inhibitors in Patients with RA: A Meta-Analysis
Abstract Number: 253

Presence of Bone Marrow Edema and Structural Lesions on Magnetic Resonance Imaging of the Sacroiliac Joints in Young Military Recruits before and after 6 Weeks of Intensive Physical Training
Abstract Number: 608

Presence of Poor Prognostic Factors May Predict Response to Abatacept in Patients with Active Psoriatic Arthritis: Results from a Post Hoc Analysis from a Phase III Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].